Videos

Jae H. Park, MD, attending physician, Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses a trial presented at the 2014 ASH Annual Meeting that explored CD19-targeted T cells as treatment for patients with relapsed, refractory B- cell ALL.

Stephan Grupp, MD, PhD, of the Children's Hospital of Philadelphia, discusses the optimal treatment settings for novel CD19-specific CAR-modified T cell therapies in patients with acute lymphoblastic leukemia.

Andre Goy, MD, MS, discusses intensive therapy for the treatment of patients with mantle cell lymphoma (MCL).

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the potential application of CAR-modified T cell technology.

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the challenges associated with CAR-modified T cells.

Andre Goy, MD, MS, from the John Theurer Cancer Center, discusses the apparent effectiveness of CD19-targeted CAR-modified T cells as a treatment for patients with various types of lymphoma.

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, explains how CAR-modified T cells can be used to treat hematologic cancers.

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses adjuvant therapy of renal cell carcinoma (RCC).

Lucio Crinò, MD, discusses the results of the PROFILE 1007 trial that compared crizotinib with standard chemotherapy as second-line therapy for advanced ALK+ non-small cell lung cancer

Renier J. Brentjens, MD, PhD, Leukemia Service, Memorial Sloan-Kettering Cancer Center, discusses the side effects of chimeric antigen receptor (CAR)–modified T cells when used to treat B-cell malignancies.

Renier J. Brentjens, MD, PhD, Leukemia Service, Memorial Sloan-Kettering Cancer Center, discusses the treatment of B-cell malignancies with chimeric antigen receptor(CAR)–modified T cells.

Catherine Bollard, MBChB, MD, Professor of Pediatrics, Medicine, and Pathology & Immunology, Baylor College of Medicine, discusses the treatment of EBV-positive lymphoma with T-cell therapy.

Nicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada, discusses the comparison of axitinib to sorafenib as first-line therapy in patients with metastatic renal cell carcinoma.

Robert J. Motzer, MD, from Memorial Sloan-Kettering Cancer Center, discusses the COMPARZ trial that compared pazopanib to sunitinib as a first-line therapy for patients with metastatic renal cell carcinoma.